Ocriplasmin intravitreal injection
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Single use vial containing ocriplasmin in solution.
Ocriplasmin is a truncated form of human plasmin produced by recombinant DNA technology in a Pichia pastoris expression system.
Drugs List
Therapeutic Indications
Uses
Treatment of vitreomacular traction
Dosage
Adults
Single dose of 0.125mg in 0.1ml of solution for injection administered by intravitreal injection to the affected eye.
Treatment with this medication into the other eye is not recommended concurrently or within 7 days of the initial injection.
Repeated administration in the same eye is not recommended.
Administration
Only 0.1ml of the total 0.3ml in the vial should be administered. Discard any excess volume prior to injection.
Contraindications
Children under 18 years
Aphakia
Exudative age-related macular degeneration
High myopia (> 8 dioptre spherical correction or axial length > 28mm)
History of rhegmatogenous retinal detachment
Intravitreous haemorrhage
Ischaemic retinopathies
Lens zonule instability
Macular holes (> 400 microns)
Ocular infection
Periocular infection
Proliferative diabetic retinopathy
Recent ocular surgery
Retinal blood vessel occlusion
Precautions and Warnings
Predisposition to uveitis
Breastfeeding
Diabetic retinopathy
Ocular trauma
Pregnancy
Severe intra-ocular inflammation
Advise visual disturbances may affect ability to drive or operate machinery
Treatment of second eye is not recommended within 7 days
For single use only
Repeated use is not recommended
Treatment to be administered under the supervision of a specialist
Monitor during the week following injection for signs of infection
Monitor intra-ocular pressure post injection and manage appropriately
Monitor visual acuity during and after treatment
Advise patient to report any unexpected changes in eye symptoms immediately
May affect the results of routine ophthalmological examinations
Patients with an epiretinal membrane, or a vitreomacular adhesion with diameter larger than 1500 microns, may experience a reduced effect of ocriplasmin.
May affect the results of routine ophthalmological examinations including full-field ERG, colour vision test (Roth 28-hue), optical coherence tomography (OCT) and ophthalmoscopy (foveal reflex). When using these tests for subsequent diagnosis or monitoring of other conditions, the effect of ocriplasmin should be considered.
Pregnancy and Lactation
Pregnancy
Use ocriplasmin with caution during pregnancy.
The manufacturer advises caution if ocriplasmin is used during pregnancy, and only when potential benefit outweighs risk. At the time of writing there is limited published information regarding the use of ocriplasmin during pregnancy. Potential risks are unknown. The systemic exposure of this medication is expected to be very low after intravitreal injection.
Lactation
Use ocriplasmin with caution during breastfeeding.
The manufacturer advises caution if ocriplasmin is used when breastfeeding. The presence of ocriplasmin in human breast milk is unknown but due to its large molecular weight, transfer is not expected (Briggs, 2015). Effects on exposed infants are unknown.
Side Effects
Anisocoria
Anterior chamber flare
Anterior chamber inflammation
Blindness (temporary)
Blurred vision
Cells in anterior chamber of eye
Chromatopsia
Conjunctival haemorrhage
Conjunctival hyperaemia
Conjunctival irritation
Conjunctival oedema
Corneal abrasion
Double vision
Dry eyes
Epitheliopathy
Eyelid oedema
Floaters
Hyphaema
Impaired vision
Increased intra-ocular pressure
Increased lacrimation
Iritis
Lens subluxation
Macular abnormalities
Macular degeneration
Macular hole
Macular oedema
Metamorphopsia
Miosis
Night blindness
Ocular discomfort
Ocular hyperaemia
Ocular inflammation
Ocular irritation
Ocular pain
Ocular pruritus
Optical coherence tomography (OCT) abnormal
Photophobia
Photopsia
Pupillary disorder
Reduced visual acuity
Retinal degeneration
Retinal detachment
Retinal disturbances
Retinal haemorrhage
Retinal oedema
Retinal tear
Scotoma
Sensation of foreign body in eye
Visual disturbances
Visual field defects
Vitreous detachment
Vitreous haemorrhage
Vitritis
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: July 2021
Reference Sources
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
Summary of Product Characteristics: Jetrea 0.375mg/0.3ml solution for injection. Inceptua AB. Revised September 2020.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.